Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian CRAMs Benefit From Global Slowdown With Increase Business

This article was originally published in PharmAsia News

Executive Summary

The contract research and manufacturing industry in India not only is weathering the global economic crisis, its business is increasing. Some foreign drug makers have stepped up their outsourcing to India to take advantage of reduced costs that can save some multinational companies as much as 40 percent. Analysts expect the CRAM business in India to reach the $3 billion mark a year from now, equal to a growth rate of 42 percent. The increase in CRAM business in India is the opposite of the experiences of other outsourcing businesses in the country. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts